STOCKHOLM, Oct. 9, 2019 /PRNewswire/ -- The board of
directors of Sedana Medical AB (publ) ("Sedana Medical" or the
"Company") has resolved to evaluate the possibilities of listing
the Company's shares on Nasdaq Stockholm's main market within 18
months.
Since 21 June 2017, Sedana
Medical's shares have traded on Nasdaq First North Growth Market
Sweden. The board considers that a listing on the main market will
enhance the Company's development opportunity.
Sedana Medical is listed on Nasdaq First North Growth Market
Sweden.
Erik Penser Bank (+46-8-463-83-00) is certified adviser to
Sedana Medical.
This information is such that Sedana Medical AB (publ) is
obliged to disclose pursuant to the EU Market Abuse Regulation. The
information was released for public disclosure, through the agency
of the contact persons above, on 9 October
2019 at 17:31 (CET).
Sedana Medical AB (publ) has developed and sells the medical
device AnaConDa, for the administration of volatile anaesthetics to
mechanically ventilated patients. A major clinical registration
study is currently ongoing to obtain market approval in
Europe for inhalation sedation in
intensive care units with the pharmaceutical IsoConDa®
(isoflurane).
Sedana Medical has direct sales in the Nordic countries,
Germany, France, UK and Spain as well as external distributors in the
rest of Europe, Canada, Australia and South
Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in
Ireland.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN THE
UNITED STATES, AUSTRALIA,
CANADA, NEW ZEALAND, HONG
KONG, JAPAN, SINGAPORE, SOUTH
AFRICA, SOUTH KOREA OR ANY
OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION
WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER
MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END
OF THE PRESS RELEASE.
Important information
This announcement is not an offer to sell or a solicitation of
any offer to buy or subscribe for any securities issued by Sedana
Medical AB (publ) (the "Company") in any jurisdiction where such
offer or sale would be unlawful. In any EEA Member State that has
implemented implemented Regulation (EU) 2017/1129 (the "Prospectus
Regulation"). This press release is not a prospectus for purposes
of the Prospectus Regulation and has not been approved by any
regulatory authority in any jurisdiction. The Company has not
authorized any offer to the public of securities in any EEA member
state and no prospectus has been or will be prepared in connection
with the directed share issue (the "Share Issue"). In any EEA
Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the
meaning of the Prospectus Regulation.
The information contained herein is not for publication or
distribution, directly or indirectly, in or into the United States, Australia, Canada, New
Zealand, Hong Kong,
Japan, Singapore, South
Africa or South Korea. This
document does not constitute an offer to sell, or a solicitation of
an offer to purchase, any securities in the United States. Any securities referred to
herein have not been and will not be registered under the U.S.
Securities Act of 1933, as amended (the "Securities Act"), and may
not be offered or sold within the United
States absent registration or an applicable exemption from,
or in a transaction not subject to, the registration requirements
of the Securities Act. There is no intention to register any
securities referred to herein in the
United States or to make a public offering of the securities
in the United States.
In the United Kingdom, this
document and any other materials in relation to the securities
described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this
document relates is available only to, and will be engaged in only
with, "qualified investors" (as defined in section 86(7) of the
Financial Services and Markets Act 2000) and who are (i) persons
having professional experience in matters relating to investments
who fall within the definition of "investment professionals" in
Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order"); or (ii) high net
worth entities falling within Article 49(2)(a) to (d) of the Order
(all such persons together being referred to as "relevant
persons"). Persons who are not relevant persons should not take any
action on the basis of this document and should not act or rely on
it.
This announcement does not identify or suggest, or purport to
identify or suggest, the risks (direct or indirect) that may be
associated with an investment in the new shares. Any investment
decision to buy or subscribe for new shares must be made solely on
the basis of publicly available information.
The information in this announcement may not be forwarded or
distributed to any other person and may not be reproduced in any
manner whatsoever. Any forwarding, distribution, reproduction or
disclosure of this information in whole or in part is unauthorised.
Failure to comply with this directive may result in a violation of
the Securities Act or the applicable laws of other
jurisdictions.
This announcement does not constitute an invitation to
underwrite, subscribe for or otherwise acquire or dispose of any
securities in any jurisdiction. This announcement does not
constitute a recommendation concerning any investor's option. Each
investor or prospective investor should conduct his, her or its own
investigation, analysis and evaluation of the business and data
described in this announcement and publicly available information.
The price and value of securities can go down as well as up. Past
performance is not a guide to future performance. Neither the
content of the Company's website nor any website accessible by
hyperlinks on the Company's website is incorporated in, or forms
part of, this announcement.
CONTACT:
For additional information, please contact:
Christer Ahlberg, CEO, Sedana
Medical AB
+46-70-675-33-30
Christer.ahlberg@sedanamedical.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/sedana-medical/r/sedana-medical-ab--publ--prepares-for-listing-on-the-nasdaq-stockholm-main-market,c2929297
The following files are available for download:
https://mb.cision.com/Main/15764/2929297/1121113.pdf
|
Release
|